![]() |
Lapatinib benefits found for HER2-positive early-stage patients
Women with early-stage, HER2-positive breast cancer who are unable to use trastuzumab may benefit from adjuvant lapatinib treatment, suggest phase III trial findings published in Lancet Oncology.
More... |
| All times are GMT -7. The time now is 05:02 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021